I’m calling shenanigans. NK platform is potentially best in...

I’m calling shenanigans.

NK platform is potentially best in class. Already 3 complete response reported. MD Anderson, the largest cancer centre in the world approached us so MD Anderson could fund a Phase 1 trial using our NK cells in a combo AML trial. Principal Investigator and CMO spoke for an hour about why this combo could be practice changing and if the results are as expected would qualify for a breakthrough therapy designation from the FDA.

CLTX therapy has so far demonstrated better efficacy than the current standard of care for Glioblastoma, as well as other IND trials in the clinic. CEO is working on bringing trial to AU.

No doubt CDH17 is their lead asset, but don’t discount the other therapies. Could be trifecta across 3 platforms, spanning 4 trials.